Browse any supplement retailer and you will find myo-inositol positioned as an answer to PCOS. The label lists 2g or 4g, sometimes alongside 400 mcg of folic acid, and rarely anything more. What it almost never addresses is that the ratio between myo-inositol and its metabolite d-chiro-inositol changes what happens inside ovarian tissue in ways that a single dose cannot fully explain.
Two molecules, one feedback loop
Inositol is a sugar alcohol the body makes from glucose and absorbs from food - mainly from fruit, beans, and whole grains. It exists in nine structural forms, but two - myo-inositol (MI) and d-chiro-inositol (DCI) - matter for PCOS because both act as second messengers in insulin signaling pathways.
MI is the dominant form in circulation. It supports the pathway that controls glucose uptake and helps FSH signaling in ovarian follicles. DCI, present at much lower concentrations in blood, plays a role in insulin-driven glycogen storage and, within the ovary, in androgen production. The body converts MI to DCI through an enzyme called epimerase - a conversion partly driven by how much insulin is in the area. In tissue with normal insulin sensitivity, this conversion stays balanced. In insulin-resistant tissue, epimerase may work faster, and the local MI-to-DCI ratio shifts.
In PCOS, researchers describe a spatial paradox: insulin resistance in the body coexists with ovarian over-sensitivity to insulin. The ovary may convert MI to DCI at a faster rate, leaving follicular cells with less MI. A lower follicular MI-to-DCI ratio reduces FSH receptor sensitivity and promotes local androgen production. This framework is set out in a 2014 review published in the European Review for Medical and Pharmacological Sciences. It is a working hypothesis supported by supplementation data, not yet a proven causal chain - but clinical trials support it.
The 40:1 figure and what it represents
The molar ratio of MI to DCI in healthy human plasma is approximately 40:1 - roughly 40 molecules of myo-inositol for every one of d-chiro-inositol. This figure has become the reference point for combined supplementation strategies. The logic is straightforward: if PCOS involves a local deviation from this ratio inside ovarian tissue, supplementing at the plasma ratio may help restore it.
A randomized controlled trial examining MI plus DCI at the 40:1 ratio found the combination effective in restoring ovarian function and metabolic balance in PCOS patients, with advantages over myo-inositol alone. A 2024 study published in PMC used the same ratio at a dose of 1,100 mg MI plus 27.6 mg DCI twice daily (total: 2,200 mg MI and 55 mg DCI per day) in women with phenotype A PCOS - the phenotype defined under Rotterdam criteria by anovulation, high androgens, and polycystic ovarian morphology. Over six months, participants showed drops in testosterone and fasting insulin, along with improvements in AMH.
An earlier trial, published in PMC in 2016, used the same dose - 1,100 mg MI plus 27.6 mg DCI twice daily - in young overweight women with PCOS. The combined protocol produced greater improvement in hormone and metabolic measures than myo-inositol alone at comparable total doses. The finding across these studies is that the ratio, not the raw dose of either compound, is what matters.
What happens when d-chiro-inositol is dosed too high
DCI is not a straight dose-dependent benefit. There is a threshold effect, and the data above that threshold shows the opposite result. This is where the ratio argument becomes important in practice.
A 2021 preclinical study gave DCI to mice at a dose corresponding to approximately 1,200 mg per day in humans. The ovaries showed cystic follicular morphology, reduced aromatase expression, and elevated serum testosterone - a PCOS-like picture caused by the very compound meant to help. Aromatase converts androgens to estrogen inside the follicle. When it is suppressed, local androgen levels rise. A 2023 clinical review raised the same concern about human data, noting that prolonged, high-dose DCI supplementation - especially in women without insulin resistance - led to poorer egg quality and lower ovarian response in clinical settings.
The direct comparison trial is also telling. A prospective randomized study (PMID 21608442) compared myo-inositol at 4,000 mg per day against d-chiro-inositol at 1,200 mg per day in women undergoing intracytoplasmic sperm injection cycles. The myo-inositol group produced significantly more mature oocytes and better embryo quality. DCI alone, at that dose, produced worse results on every measured outcome.
The doses that clinical trials actually used
The supplementation research is not uniform, and the figures on retail labels often do not match the protocols that were studied. These are the main approaches in the research.
- Myo-inositol alone: 4,000 mg per day (2,000 mg twice daily), typically combined with 400 mcg folic acid. This is the dose from the randomized double-blind placebo-controlled trial by Gerli and colleagues (PMID 18074942), which reported increased ovulation frequency and a shorter time to first ovulation versus placebo over three months in women with PCOS.
- Combined 40:1, lower total dose: 2,200 mg MI plus 55 mg DCI per day, taken as 1,100 mg MI and 27.6 mg DCI twice daily. Used in the 2016 overweight PCOS trial and the 2024 phenotype A study cited above.
- Combined 40:1, higher total dose: 4,000 mg MI plus 100 mg DCI per day, taken as 2,000 mg MI and 50 mg DCI twice daily. Used in some later combined-therapy protocols from the same Italian research groups.
No published trial has compared all three approaches directly in the same PCOS population. The research supports each approach under different conditions, and choosing between them is not a product decision - it is a clinical one based on individual metabolism.
Phenotype matters more than the product label
PCOS spans at least four phenotypes under the Rotterdam criteria, ranging from the full combination of anovulation, high androgens, and polycystic ovarian morphology to milder two-feature presentations. The metabolic burden and the degree of insulin resistance differ significantly between them. Treating all four with the same supplement regimen ignores their different metabolic needs.
The combined 40:1 approach works best in women with PCOS who also have insulin resistance or metabolic syndrome features. In this group, the ovarian MI-DCI imbalance likely comes from accelerated epimerase activity, and restoring the normal ratio has the strongest theoretical and research support. Improvements in fasting insulin, testosterone, and menstrual regularity have been reported across multiple trials in this population.
For lean women with PCOS and normal insulin sensitivity, the evidence is unclear. A 2020 clinical trial (PMID 32989863) found that the 40:1 combination offered no real advantage over myo-inositol alone in normal-weight, non-insulin-resistant PCOS patients. Local DCI availability is likely adequate in non-insulin-resistant ovarian tissue; adding extra DCI might raise the follicular ratio too high instead of restoring it. For this group, myo-inositol alone at 4,000 mg per day is the more studied option.
This distinction does not show up in most supplement labels. Products positioned broadly for PCOS tend to use the 40:1 ratio as a universal recommendation, even though research does not fully support this for all types of PCOS. If you are interested in other research-based approaches to androgen balance in PCOS, the Ayurnomics Journal has a detailed piece on spearmint tea and what the clinical data show about free testosterone levels. And for the relationship between cortisol, HPA axis activity, and cycle regularity - a connection that often comes up in PCOS discussions - the piece on ashwagandha timing and cortisol biology is worth reading alongside this one.
If you are taking metformin or another prescription medication for PCOS, or are pregnant or breastfeeding, discuss inositol supplementation with your clinician before starting. The dose that applies to your specific phenotype and metabolic profile is not something a product label can determine, and the interaction data in these populations remain limited.
For more on women's hormonal health, explore the Hormonal Balance collection.
Vuoi altri contenuti come questo? Unisciti all'Inner Circle e ricevi un articolo curato ogni domenica.